ORTEXORTEX News
Tracking APG? Get live short interest, options flow, and signals on ORTEX.Sign up free →
AP
Trader NoteAPG

APi Group jumps 12% after earnings beat as analysts lift targets

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 3 min readdata as of 31 Oct 2026, 20:50

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

APi Group delivered its third-quarter results on October 29, and the market's verdict was swift: shares rose 12.4% over the week to close at $44.34, a move that ran sharply against the grain of the company's closest peers, where VMI dropped 3% and IESC fell 3.5% over the same period.

The analyst response to the print has been one of the cleanest post-earnings consensus shifts seen in the sector this week. JP Morgan's Stephen Tusa raised his target from $50 to $55 and kept his Overweight. Citigroup's Andrew Kaplowitz went from $55 to $57, also maintaining Buy. Wells Fargo lifted its target from $53 to $60, the most aggressive move in the group. Truist moved from $55 to $58. All four actions were filed on October 30, the morning after results, and all kept their existing positive ratings intact. The mean price target across the Street now stands at $54.73, implying roughly 23% upside from Friday's close. That the upgrades were unanimous in direction, and that none of the covering firms used the rally as a moment to trim conviction, suggests the result cleared the bar by a margin.

Positioning tells an interesting story in the context of that move. Short interest climbed 12.7% over the past week to reach 2.7% of the free float, the sharpest weekly jump in the series going back 30 days, and it is 1.6 standard deviations above the company's typical weekly move over the past year. That build-up happened entirely before the results, echoing the pre-earnings put/call ratio that had spiked to a 52-week high of 9.58 on October 29 before settling back to 9.26 on October 30. The 20-day mean for the PCR stands at 3.92, and the current reading of 9.26 is still nearly 1.7 standard deviations above that average. Options traders had clearly positioned for a range of outcomes, and the skew toward puts heading into the print was one of the most pronounced in the past year. Those positions now sit against a stock that has already re-rated sharply higher. The borrow market, for its part, remains completely relaxed: availability at 2,221% means there are more than 22 shares available in the lending pool for every one currently borrowed, and borrowing costs at 0.47% are negligible, up 32% on the week but from an already low base.

The ownership register carries one headline worth noting. Sir Martin Franklin holds an active 13D filing on APi Group, the highest-signal designation on the SEC register, reflecting activist or controlling intent rather than passive accumulation. His latest disclosed stake stood at 11.5% of shares, down from 12.7% in the prior filing. That decline tracks with a June 11 open-market sale of 2 million shares at $42.08, worth roughly $84 million, which was filed without a 10b5-1 plan, making it a discretionary transaction rather than a pre-scheduled one. Two other directors, James Lillie and Ian Ashken, also sold material positions in early August, each under pre-arranged 10b5-1 plans. Net insider activity over the past 90 days adds up to roughly 2.67 million shares sold and $111 million in net proceeds. The 13D designation means Franklin's intentions remain on the register; the disclosure caveat applies: stakes are as last disclosed around the 5% threshold, and positions can shift without triggering a new filing.

The ORTEX alt data layer flags a notable spike in retail attention: the z-score on Wikipedia and ORTEX page views for APi Group reached 4.28 as of October 22, well above any comparable reading in the prior 90 days. That kind of attention surge often accompanies earnings catalysts and the share price move that followed. Separately, the company recorded its largest Q2 buyback spend since 2022, at $66 million, a fact that speaks to management's capital allocation posture heading into the second half of the year.

The next earnings date is pencilled in for February 25, 2027, giving the Street 117 days to reassess whether the Q3 result represents a durable inflection or a quarter-specific beat. The tension worth watching between now and then is whether the elevated put/call ratio, which has not fully unwound despite the stock's 12% gain, reflects residual hedging that will roll off naturally or something more structural in how institutional holders are managing their positions into year-end.

Stocks in this article

See the live data behind this article on ORTEX.

Open APG on ORTEX →

How this article was generated

Generated
31 Oct 2026, 20:50
Data as of
31 Oct 2026, 20:50
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt DataPrevious Mi Articles

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.